Retrieved on:
Thursday, February 22, 2024
Acquisition,
SAN,
Cancer,
ADS,
AstraZeneca,
Time in New York,
Cayman Islands,
Plan,
Autoimmune disease,
Agreement,
Milestone,
Bank,
Form 6-K,
Form,
CICA,
American depositary receipt,
Companies Act,
Security (finance),
CVR,
Sub The acquisition was structured as a merger of Merger Sub with and into the Company with the Company surviving the merger as a wholly owned subsidiary of Parent (the “Merger”).
Key Points:
- The acquisition was structured as a merger of Merger Sub with and into the Company with the Company surviving the merger as a wholly owned subsidiary of Parent (the “Merger”).
- As a result of the Merger, the Company ceased to be a publicly traded company and became a wholly owned subsidiary of Parent.
- Such letters of transmittal must be completed before such holders can receive the applicable merger consideration.
- Certificated ADS holders should wait to receive the letters of transmittal before surrendering their ADSs.
Retrieved on:
Tuesday, February 20, 2024
Transaction,
SAN,
Cayman Islands,
Plan,
Autoimmune disease,
Registrar,
Proxy,
Cayman,
Companies Act,
EGM,
Agreement,
Cancer,
Airline Pursuant to the Merger Agreement, in accordance with the applicable provisions of the Companies Act (As Revised) of the Cayman Islands, Merger Sub will merge with and into the Company at the effective time of the Merger, with the Company continuing as the surviving company and becoming a wholly owned subsidiary of the Parent (the “Merger”).
Key Points:
- Pursuant to the Merger Agreement, in accordance with the applicable provisions of the Companies Act (As Revised) of the Cayman Islands, Merger Sub will merge with and into the Company at the effective time of the Merger, with the Company continuing as the surviving company and becoming a wholly owned subsidiary of the Parent (the “Merger”).
- Each shareholder has one vote for each Ordinary Share.
- The Merger Agreement, the Plan of Merger and the Transactions, were approved by approximately 99.9% of the total votes cast at the EGM.
- The Merger is expected to close on or around February 22, 2024, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement.
Patient,
SAN,
IIT,
Society,
Cancer,
Autoimmune disease,
RRMM,
CD19,
IND,
Food,
Multiple myeloma,
Safety,
FDA,
BCMA,
Pharmaceutical industry “We are extremely pleased to receive our third U.S. IND clearance for our lead FasTCAR candidate GC012F, now expanding company-sponsored investigation into early-line multiple myeloma,” said Dr. William Cao, founder, Chairman and Chief Executive Officer of Gracell.
Key Points:
- “We are extremely pleased to receive our third U.S. IND clearance for our lead FasTCAR candidate GC012F, now expanding company-sponsored investigation into early-line multiple myeloma,” said Dr. William Cao, founder, Chairman and Chief Executive Officer of Gracell.
- This is the third U.S. IND clearance for GC012F.
- In addition to the ELMM study, GC012F is being evaluated in an ongoing Phase 1b/2 U.S. IND study for the treatment of relapsed/refractory multiple myeloma (RRMM) and in a Phase 1/2 clinical trial for the treatment of refractory systemic lupus erythematosus (rSLE) that will initiate in 2024.
- GC012F is also being evaluated in four investigator-initiated trials (IIT) for the treatment of rSLE, RRMM, newly-diagnosed multiple myeloma (NDMM) and B-cell non-Hodgkin lymphoma (B-NHL).
Retrieved on:
Saturday, January 20, 2024
It is free and there is no cost or obligation to you.
Key Points:
- It is free and there is no cost or obligation to you.
- Under the terms of the agreement, AXNX shareholders will receive $71.00 in cash per share they own.
- Codorus Valley Bancorp, Inc. (Nasdaq: CVLY ), relating to its proposed sale to Orrstown Financial Services, Inc.
- Under the terms of the agreement, CVLY shareholders are expected to own approximately 44% of the outstanding shares of the combined company.
Retrieved on:
Wednesday, January 17, 2024
If you are a PGT shareholder, click here to learn more about your rights and options .
Key Points:
- If you are a PGT shareholder, click here to learn more about your rights and options .
- If you are a Karuna shareholder, click here to learn more about your rights and options .
- If you are a Theseus shareholder, click here to learn more about your rights and options .
- Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
Retrieved on:
Tuesday, January 16, 2024
Brodsky,
Harpoon,
ADS,
Johnson & Johnson,
AstraZeneca,
BSX,
JNJ,
J&J,
Boston Scientific,
AZN,
MRK,
Security (finance) BALA CYNWYD, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
Key Points:
- BALA CYNWYD, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
- If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
- Under the terms of the agreement, Ambrx will be acquired by Johnson & Johnson (“J&J”) (NYSE – JNJ).
- Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.
Retrieved on:
Saturday, January 13, 2024
If you are a RayzeBio shareholder, click here to learn more about your rights and options .
Key Points:
- If you are a RayzeBio shareholder, click here to learn more about your rights and options .
- If you are a Callon shareholder, click here to learn more about your rights and options .
- If you are a Via shareholder, click here to learn more about your rights and options .
- Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
Retrieved on:
Wednesday, January 10, 2024
If you are a Hawaiian shareholder, click here to learn more about your rights and options .
Key Points:
- If you are a Hawaiian shareholder, click here to learn more about your rights and options .
- If you are an Icosavax shareholder, click here to learn more about your rights and options .
- If you are a PGT shareholder, click here to learn more about your rights and options .
- Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
Under the terms of the agreement, AXNX shareholders will receive $71.00 in cash per share they own.
Key Points:
- Under the terms of the agreement, AXNX shareholders will receive $71.00 in cash per share they own.
- Under the terms of the agreement, BVH shareholders will receive $75.00 in cash per share they own.
- Codorus Valley Bancorp, Inc. (Nasdaq: CVLY ), relating to its proposed sale to Orrstown Financial Services, Inc.
- Under the terms of the agreement, CVLY shareholders are expected to own approximately 44% of the outstanding shares of the combined company.
ADS,
Harpoon,
Johnson & Johnson,
Brodsky,
AstraZeneca,
J&J,
Boston Scientific,
JNJ,
AZN,
MRK,
BSX,
Security (finance) BALA CYNWYD, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
Key Points:
- BALA CYNWYD, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
- If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
- Under the terms of the agreement, Ambrx will be acquired by Johnson & Johnson (“J&J”) (NYSE – JNJ).
- Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.
